Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy & Immunology
U.S. FDA approves Clarinex-D 12 Hour
February 27th, 2006
Schering-Plough Corp. (SGP) announced that the U.S. Food & Drug Administration (FDA) has approved Clarinex-D 12 Hour (desloratadine 2.5 mg and pseudoephedrine sulfate, USP 120 mg) extended-release tablets for the relief of nasal and non-nasal symptoms of seasonal allergic rhinitis (outdoor allergies), including nasal congestion, in patients 12 years of age and older. Clarinex-D 12 Hour will be available nationwide in March 2006, in time for the spring allergy season. The new treatment option addresses an important need for allergy sufferers, who indicate that nasal congestion is the most bothersome symptom of allergic rhinitis. In addition, a survey of 1000 adults with...
Source: Pharma Business Week (2006-02-27)
|
